Kuwahara Jon 4
4 · Novus Therapeutics, Inc. · Filed Sep 15, 2020
Insider Transaction Report
Form 4
Kuwahara Jon
See Remarks
Transactions
- Award
Stock Option (Right to Buy)
2020-09-11+2,145.264→ 2,145.264 totalExercise: $500.00Exp: 2030-09-11→ Series X1 Convertible Preferred Stock (2,145.264 underlying)
Footnotes (2)
- [F1]This option represents a right to purchase a total of 2,145.264 shares of the Issuer's Series X1 Convertible Preferred Stock, one quarter of which will become fully vested and exercisable on September 11, 2021, with the remaining 1,608.948 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. The Reporting Person's ability to exercise the option will be subject to stockholder approval under Nasdaq Marketplace Rule 5635(c).
- [F2]Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer.